Cleveland Clinic and Aspira Women’s Health have entered into a collaboration to support the development of AI-powered diagnostics for women’s health.
Under the agreement, Cleveland Clinic and Aspira Women’s Health will collaborate on research focused on discovering and validating biomarker signatures and developing analytical models aimed at improving diagnostic accuracy and patient care, according to a May 26 news release.
The partnership will also support future work in biomarker discovery, translational development and clinical research initiatives. The initiative will be jointly led by Kevin Elias, MD, the Lilli and Seth Harris Endowed Chair for Ovarian Cancer Research at Cleveland Clinic, and Todd Pappas, PhD, chief scientific officer of Aspira Women’s Health.
The organizations said the collaboration is intended to expand access to patient samples, strengthen clinical validation capabilities and accelerate the development of next-generation multiomic diagnostics across women’s health.
